The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
Open accessAbstract
Purpose: Half the patients with acute myeloid leukemia (AML) who achieve complete remission (CR), ultimately relapse. Residual treatment-surviving leukemia is considered responsible for the outgrowth of AML. In many retrospective studies, detection of minimal residual disease (MRD) has been shown to enable identification of these poor-outcome patients by showing its independent prognostic impact. Most studies focus on molecular markers or analyze data in retrospect. This study establishes the value of immunophenotypically assessed MRD in the context of a multicenter clinical trial in adult AML with sample collection and analysis performed in a few specialized centers. Patients and Methods: In adults (younger than age 60 years) with AML enrolled onto the Dutch-Belgian Hemato-Oncology Cooperative Group/Swiss Group for Clinical Cancer Research Acute Myeloid Leukemia 42A study, MRD was evaluated in bone marrow samples in CR (164 after induction cycle 1, 183 after cycle 2, 124 after consolidation therapy). Results: After all courses of therapy, low MRD values distinguished patients with relatively favorable outcome from those with high relapse rate and adverse relapse-free and overall survival. In the whole patient group and in the subgroup with intermediate-risk cytogenetics, MRD was an independent prognostic factor. Multivariate analysis after cycle 2, when decisions about consolidation treatment have to be made, confirmed that high MRD values (> 0.1% of WBC) were associated with a higher risk of relapse after adjustment for consolidation treatment time-dependent covariate risk score and early or later CR. Conclusion: In future treatment studies, risk stratification should be based not only on risk estimation assessed at diagnosis but also on MRD as a therapy-dependent prognostic factor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370
Self-citationRubnitz, J. E., Inaba, H., Dahl, G., Ribeiro, R. C., Bowman, W. P., Taub, J., Pounds, S., Razzouk, B. I., Lacayo, N. J., Cao, X., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70090-5 · Cited by 584
Cumulative Incidence in Competing Risks Data and Competing Risks Regression Analysis
Kim, H. T. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1210 · Cited by 507
van Rhenen, A., van Dongen, G. A. M. S., Kelder, A., Rombouts, E. J., Feller, N., Moshaver, B., Walsum, M. S.-V., Zweegman, S., Ossenkoppele, G. J., & Jan Schuurhuis, G. (2007) · Blood · doi:10.1182/blood-2007-03-083048 · Cited by 439
Self-citationvan Rhenen, A., Feller, N., Kelder, A., Westra, A. H., Rombouts, E., Zweegman, S., van der Pol, M. A., Waisfisz, Q., Ossenkoppele, G. J., & Schuurhuis, G. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0468 · Cited by 375
Self-citationSan Miguel, J. F., Vidriales, M. B., López-Berges, C., Dı́az-Mediavilla, J., Gutiérrez, N., Cañizo, C., Ramos, F., Calmuntia, M. J., Pérez, J. J., González, M., et al. (2001) · Blood · doi:10.1182/blood.v98.6.1746 · Cited by 335
Venditti, A., Buccisano, F., Del Poeta, G., Maurillo, L., Tamburini, A., Cox, C., Battaglia, A., Catalano, G., Del Moro, B., Cudillo, L., et al. (2000) · Blood · doi:10.1182/blood.v96.12.3948 · Cited by 275
Kern, W., Voskova, D., Schoch, C., Hiddemann, W., Schnittger, S., & Haferlach, T. (2004) · Blood · doi:10.1182/blood-2004-03-1036 · Cited by 268
van Rhenen, A., Moshaver, B., Kelder, A., Feller, N., Nieuwint, A. W. M., Zweegman, S., Ossenkoppele, G. J., & Schuurhuis, G. J. (2007) · Leukemia · doi:10.1038/sj.leu.2404754 · Cited by 193
Self-citationFeller, N., van der Pol, M. A., van Stijn, A., Weijers, G. W. D., Westra, A. H., Evertse, B. W., Ossenkoppele, G. J., & Schuurhuis, G. J. (2004) · Leukemia · doi:10.1038/sj.leu.2403405 · Cited by 184
Self-citationIndependent prognostic factors for AML outcome
Grimwade, D., & Hills, R. K. (2009) · Hematology · doi:10.1182/asheducation-2009.1.385 · Cited by 180
Maurillo, L., Buccisano, F., Del Principe, M. I., Del Poeta, G., Spagnoli, A., Panetta, P., Ammatuna, E., Neri, B., Ottaviani, L., Sarlo, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9814 · Cited by 179
Langebrake, C., Creutzig, U., Dworzak, M. N., Hrušák, O., Mejstříková, E., Griesinger, F., Zimmermann, M., & Reinhardt, D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4312 · Cited by 156
van der Velden, V. H. J., van der Sluijs‐Gelling, A. J., Gibson, B. E. S., Marvelde, J. G. T., Hoogeveen, P. G., Hop, W. C. J., Wheatley, K., Bierings, M., Schuurhuis, G. J., de Graaf, S. S. N., et al. (2010) · Leukemia · doi:10.1038/leu.2010.153 · Cited by 143
Self-citationClinical significance of residual disease during treatment in childhood acute myeloid leukaemia
Coustan‐Smith, E., Ribeiro, R. C., Rubnitz, J. E., Razzouk, B. I., Pui, C., Pounds, S. B., Andreánsky, M., Behm, F. G., Raimondi, S. C., Shurtleff, S. A., et al. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04610.x · Cited by 142
Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms
Ossenkoppele, G. J., van de Loosdrecht, A. A., & Schuurhuis, G. J. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08595.x · Cited by 117
Self-citationMonitoring of minimal residual disease in acute myeloid leukemia
Kern, W., Haferlach, C., Haferlach, T., & Schnittger, S. (2007) · Cancer · doi:10.1002/cncr.23128 · Cited by 112
Pabst, T., Vellenga, E., van Putten, W., Schouten, H. C., Graux, C., Vekemans, M., Biemond, B. J., Sonneveld, P., Passweg, J. R., Verdonck, L. F., et al. (2012) · Blood · doi:10.1182/blood-2011-11-389841 · Cited by 95
Self-citationStatus of minimal residual disease testing in childhood haematological malignancies
Campana, D. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07350.x · Cited by 72
Minimal residual disease monitoring by flow cytometry
Vídriales, M., Miguel, J. F. S., Órfão, A., Coustan‐Smith, E., & Campana, D. (2003) · Best Practice & Research Clinical Haematology · doi:10.1016/s1521-6926(03)00067-7 · Cited by 71
Implication of the Molecular Characterization of Acute Myeloid Leukemia
Döhner, H. (2007) · Hematology · doi:10.1182/asheducation-2007.1.412 · Cited by 57
Monitoring of minimal residual disease in acute myeloid leukemia
Buccisano, F., Maurillo, L., Spagnoli, A., Principe, M. I. D., Ceresoli, E., Lo‐Coco, F., Arcese, W., Amadori, S., & Venditti, A. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283311856 · Cited by 34
Cited by
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Self-citationDöhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., et al. (2022) · Blood · doi:10.1182/blood.2022016867 · Cited by 3,279
Self-citationSchuurhuis, G. J., Heuser, M., Freeman, S., Béné, M.-C., Buccisano, F., Cloos, J., Grimwade, D., Haferlach, T., Hills, R. K., Hourigan, C. S., et al. (2018) · Blood · doi:10.1182/blood-2017-09-801498 · Cited by 1,041
Self-citationMolecular Minimal Residual Disease in Acute Myeloid Leukemia
Jongen-Lavrencic, M., Grob, T., Hanekamp, D., Kavelaars, F. G., al Hinai, A., Zeilemaker, A., Erpelinck-Verschueren, C. A. J., Gradowska, P. L., Meijer, R., Cloos, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716863 · Cited by 786
Self-citationShort, N. J., Rytting, M. E., & Cortes, J. E. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31041-9 · Cited by 781
Metadata
- Authors
- Terwijn, M., van Putten, W. L. J., Kelder, A., van der Velden, V. H. J., Brooimans, R. A., Pabst, T., Maertens, J., Boeckx, N., de Greef, G. E., Valk, P. J. M., Preijers, F. W. M. B., Huijgens, P. C., Dräger, A. M., Schanz, U., Jongen-Lavrecic, M., Biemond, B. J., Passweg, J. R., van Gelder, M., Wijermans, P., Graux, C., Bargetzi, M., Legdeur, M.-C., Kuball, J., de Weerdt, O., Chalandon, Y., Hess, U., Verdonck, L. F., Gratama, J. W., Oussoren, Y. J. M., Scholten, W. J., Slomp, J., Snel, A. N., Vekemans, M.-C., Löwenberg, B., Ossenkoppele, G. J., & Schuurhuis, G. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-11-01
- Volume
- 31
- Issue
- 31
- Pages
- 3889-3897
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2128541003
- Cited by
- 442
- References
- 25
- FWCI
- 21.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.